183 related articles for article (PubMed ID: 27553419)
1. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
Gillard P; Yang PC; Danilovits M; Su WJ; Cheng SL; Pehme L; Bollaerts A; Jongert E; Moris P; Ofori-Anyinam O; Demoitié MA; Castro M
Tuberculosis (Edinb); 2016 Sep; 100():118-127. PubMed ID: 27553419
[TBL] [Abstract][Full Text] [Related]
2. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
Kumarasamy N; Poongulali S; Beulah FE; Akite EJ; Ayuk LN; Bollaerts A; Demoitié MA; Jongert E; Ofori-Anyinam O; Van Der Meeren O
Medicine (Baltimore); 2018 Nov; 97(45):e13120. PubMed ID: 30407329
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
Penn-Nicholson A; Geldenhuys H; Burny W; van der Most R; Day CL; Jongert E; Moris P; Hatherill M; Ofori-Anyinam O; Hanekom W; ; Bollaerts A; Demoitie MA; Kany Luabeya AK; De Ruymaeker E; Tameris M; Lapierre D; Scriba TJ
Vaccine; 2015 Jul; 33(32):4025-34. PubMed ID: 26072017
[TBL] [Abstract][Full Text] [Related]
5. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01
Ullah I; Bibi S; Ul Haq I; Safia ; Ullah K; Ge L; Shi X; Bin M; Niu H; Tian J; Zhu B
Front Immunol; 2020; 11():1806. PubMed ID: 33133057
[No Abstract] [Full Text] [Related]
6. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
[TBL] [Abstract][Full Text] [Related]
7. Final Analysis of a Trial of M72/AS01
Tait DR; Hatherill M; Van Der Meeren O; Ginsberg AM; Van Brakel E; Salaun B; Scriba TJ; Akite EJ; Ayles HM; Bollaerts A; Demoitié MA; Diacon A; Evans TG; Gillard P; Hellström E; Innes JC; Lempicki M; Malahleha M; Martinson N; Mesia Vela D; Muyoyeta M; Nduba V; Pascal TG; Tameris M; Thienemann F; Wilkinson RJ; Roman F
N Engl J Med; 2019 Dec; 381(25):2429-2439. PubMed ID: 31661198
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Safety of the M72/AS01
Ji Z; Jian M; Chen T; Luo L; Li L; Dai X; Bai R; Ding Z; Bi Y; Wen S; Zhou G; Abi ME; Liu A; Bao F
Front Immunol; 2019; 10():2089. PubMed ID: 31552037
[No Abstract] [Full Text] [Related]
9. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
Montoya J; Solon JA; Cunanan SR; Acosta L; Bollaerts A; Moris P; Janssens M; Jongert E; Demoitié MA; Mettens P; Gatchalian S; Vinals C; Cohen J; Ofori-Anyinam O
J Clin Immunol; 2013 Nov; 33(8):1360-75. PubMed ID: 24142232
[TBL] [Abstract][Full Text] [Related]
10. Phase 2b Controlled Trial of M72/AS01
Van Der Meeren O; Hatherill M; Nduba V; Wilkinson RJ; Muyoyeta M; Van Brakel E; Ayles HM; Henostroza G; Thienemann F; Scriba TJ; Diacon A; Blatner GL; Demoitié MA; Tameris M; Malahleha M; Innes JC; Hellström E; Martinson N; Singh T; Akite EJ; Khatoon Azam A; Bollaerts A; Ginsberg AM; Evans TG; Gillard P; Tait DR
N Engl J Med; 2018 Oct; 379(17):1621-1634. PubMed ID: 30280651
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
Idoko OT; Owolabi OA; Owiafe PK; Moris P; Odutola A; Bollaerts A; Ogundare E; Jongert E; Demoitié MA; Ofori-Anyinam O; Ota MO
Tuberculosis (Edinb); 2014 Dec; 94(6):564-78. PubMed ID: 25305000
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.
Kumarasamy N; Poongulali S; Bollaerts A; Moris P; Beulah FE; Ayuk LN; Demoitié MA; Jongert E; Ofori-Anyinam O
Medicine (Baltimore); 2016 Jan; 95(3):e2459. PubMed ID: 26817879
[TBL] [Abstract][Full Text] [Related]
13. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
Spertini F; Audran R; Lurati F; Ofori-Anyinam O; Zysset F; Vandepapelière P; Moris P; Demoitié MA; Mettens P; Vinals C; Vastiau I; Jongert E; Cohen J; Ballou WR
Tuberculosis (Edinb); 2013 Mar; 93(2):179-88. PubMed ID: 23219236
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
Front Immunol; 2018; 9():564. PubMed ID: 29632533
[TBL] [Abstract][Full Text] [Related]
17. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
18. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
Day CL; Tameris M; Mansoor N; van Rooyen M; de Kock M; Geldenhuys H; Erasmus M; Makhethe L; Hughes EJ; Gelderbloem S; Bollaerts A; Bourguignon P; Cohen J; Demoitié MA; Mettens P; Moris P; Sadoff JC; Hawkridge A; Hussey GD; Mahomed H; Ofori-Anyinam O; Hanekom WA
Am J Respir Crit Care Med; 2013 Aug; 188(4):492-502. PubMed ID: 23306546
[TBL] [Abstract][Full Text] [Related]
19. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
20. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
